SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Spruce Biosciences, Inc. (SPRB) has a negative trailing P/E of -1.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 10.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -76.83%, forward earnings yield 9.51%. PEG 0.14 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (100/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.14); analyst target implies upside (+232.4%).
- Forward P/E 10.5 — analysts expect a return to profitability with estimated EPS of $6.69 for FY2029.
- PEG Ratio 0.14 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -76.83% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 9.51% as earnings recover.
- Analyst consensus target $234.00 (+232.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 50/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SPRB
Valuation Multiples
P/E (TTM)-1.3
Forward P/E10.5
PEG Ratio0.14
Forward PEG0.14
P/B Ratio1.19
P/S Ratio0.00
EV/EBITDA0.3
Per Share Data
EPS (TTM)$-50.83
Forward EPS (Est.)$6.69
Book Value / Share$55.46
Revenue / Share$0.00
FCF / Share$-43.47
Yields & Fair Value
Earnings Yield-76.83%
Forward Earnings Yield9.51%
Dividend Yield0.00%
Analyst Target$234.00 (+232.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2018 |
-2.6 |
0.00 |
-1.42 |
0.00 |
- |
| 2019 |
-55.8 |
0.58 |
-24.09 |
0.00 |
- |
| 2020 |
-37.3 |
-0.32 |
7.38 |
0.00 |
- |
| 2021 |
-4.8 |
-0.12 |
1.82 |
0.00 |
- |
| 2022 |
-1.1 |
-0.20 |
0.73 |
0.00 |
- |
| 2023 |
-2.3 |
-0.08 |
1.44 |
10.90 |
- |
| 2024 |
-0.3 |
-0.08 |
0.59 |
3.44 |
- |
| 2025 |
-1.7 |
0.04 |
1.57 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-2.21 |
$0.00 |
$-9.86M |
- |
| 2019 |
$-0.30 |
$0.00 |
$-13.24M |
- |
| 2020 |
$-0.65 |
$0.00 |
$-30.03M |
- |
| 2021 |
$-0.91 |
$0.00 |
$-42.69M |
- |
| 2022 |
$-0.96 |
$0.00 |
$-46.18M |
- |
| 2023 |
$-1.24 |
$10.09M |
$-47.92M |
-475% |
| 2024 |
$-1.29 |
$4.91M |
$-53.04M |
-1079.9% |
| 2025 |
$-50.83 |
$0.00 |
$-38.97M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-36.72 |
$-38.66 – $-34.78 |
$53.75M |
$17.67M – $143.13M |
3 |
| 2027 |
$-31.81 |
$-32.05 – $-31.56 |
$45.7M |
$24.75M – $67.75M |
3 |
| 2028 |
$-5.49 |
$-17.36 – $-0.70 |
$33.7M |
$11.08M – $89.73M |
1 |
| 2029 |
$6.69 |
$0.85 – $21.15 |
$60.6M |
$19.92M – $161.36M |
1 |
| 2030 |
$11.78 |
$1.50 – $37.24 |
$88.6M |
$29.12M – $235.91M |
1 |
